monovalent (RSV) unlicensed comparator

Phase 1Biologic

VVicebio Australia Proprietary Limited

monovalent (RSV) unlicensed comparator is one of 26 biologic programs targeting Vaccine. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VaccineRecruiting

VaccinePhase 1

Recruiting

Competition

Competitive Landscape

36 competitors in Vaccine

#DrugCompanyPhaseTrials

Rotarix ™

GSK

Phase 3

5 2

Havrix

GSK

Phase 3

1 3

Rotateq

Merck & Co.

Phase 3

3 4

Vaxelis Vaccine

Sanofi

Phase 3

3 5

Varivax

GSK

Phase 3

3 6

M-M-R II Vaccine

Sanofi

Phase 3

2 7

Priorix

GSK

Phase 3

1 8

Trumenba

Pfizer

Phase 3

1 9

Bayer Aspirin

Bayer

Phase 1

1 10

Varivax Vaccine

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Vaccine

NCT07295028

Clinical

Trials by Indication[1]

Vaccine1 trial

Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults

Recruiting·VVicebio Australia Proprietary Limited·Phase 1·NCT07295028·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for monovalent (RSV) unlicensed comparator. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — monovalent (RSV) unlicensed comparator compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for monovalent (RSV) unlicensed comparator. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vicebio Australia Proprietary Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: VVicebio Australia Proprietary Limited

monovalent (RSV) unlicensed comparator

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Vaccine1 trial

References

Drug Info

Quick Facts

Related News